Insider transactions

EDGAR

Apogee Therapeutics, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
72 transactions, 2,149,000 shares
Sum of shares × price per share: 171,914,127.22

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 151

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-09-03 Filed 2026-09-03Shah Nimish P Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)1,750,000135.11
236,442,500

Derived: shares × price per share. Exact value 236442500.00.

0Indirect (I) See footnoteNo
F1, F2
  • F1 The reported securities, which were disposed of in connection with the acquisition of the Issuer by AbbVie Inc. (the Merger), represent (i) 460,075 shares of the Issuer's common stock (Common Stock) held by Venrock Healthcare Capital Partners III, L.P. (VHCP III), (ii) 46,025 shares held by VHCP Co-Investment Holdings III, LLC (VHCP Co-III) and (iii) 1,243,900 shares held by Venrock Healthcare Capital Partners EG, L.P. (VHCP EG).
  • F2 VHCP Management III, LLC (VHCPM III) is the sole general partner of VHCP III and the sole manager of VHCP Co-III. VHCP Management EG, LLC (VHCPM EG) is the sole general partner of VHCP EG. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM III and VHCPM EG. Dr. Koh, Mr. Shah, VHCPM III and VHCPM EG disclaim beneficial ownership over all shares held by VHCP III, VHCP Co-III, and VHCP EG, except to the extent of their respective indirect pecuniary interests therein.
Open filing 0001140361-26-035608 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Shah Nimish P Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Non-Voting Common Stock — underlying Common Stock (6,743,321) — exercise price 0
Disposed (D)6,743,321135.11
911,090,100.31

Derived: shares × price per share. Exact value 911090100.31.

0Indirect (I) See footnoteNo
F3, F4, F2
  • F3 The Non-Voting Common Stock was convertible at any time and had no expiration date.
  • F4 The reported securities, which were disposed of in connection with the Merger, represent (i) 2,495,319 shares of Non-Voting Common Stock held directly by VHCP III, (ii) 249,522 shares of Non-Voting Common Stock held directly by VHCP Co-III and (iii) 3,998,480 shares of Non-Voting Common Stock held directly by VHCP EG.
  • F2 VHCP Management III, LLC (VHCPM III) is the sole general partner of VHCP III and the sole manager of VHCP Co-III. VHCP Management EG, LLC (VHCPM EG) is the sole general partner of VHCP EG. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM III and VHCPM EG. Dr. Koh, Mr. Shah, VHCPM III and VHCPM EG disclaim beneficial ownership over all shares held by VHCP III, VHCP Co-III, and VHCP EG, except to the extent of their respective indirect pecuniary interests therein.
Open filing 0001140361-26-035608 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Shah Nimish P Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (47,758) — exercise price 17
Disposed (D)47,758——0Direct (D) No
F6, F5, F7
  • F6 Each reported option and warrant was disposed of in connection with the Merger in exchange for a cash payment equal to the excess of $135.11 (the per share merger consideration) over the exercise price of such option or warrant.
  • F5 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
  • F7 Under an agreement between the Reporting Person and Venrock Management, LLC (the Management Company), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.
Open filing 0001140361-26-035608 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Shah Nimish P Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,370) — exercise price 43.85
Disposed (D)10,370——0Direct (D) No
F6, F5, F7
  • F6 Each reported option and warrant was disposed of in connection with the Merger in exchange for a cash payment equal to the excess of $135.11 (the per share merger consideration) over the exercise price of such option or warrant.
  • F5 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
  • F7 Under an agreement between the Reporting Person and Venrock Management, LLC (the Management Company), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.
Open filing 0001140361-26-035608 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Shah Nimish P Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (14,461) — exercise price 41.66
Disposed (D)14,461——0Direct (D) No
F6, F5, F7
  • F6 Each reported option and warrant was disposed of in connection with the Merger in exchange for a cash payment equal to the excess of $135.11 (the per share merger consideration) over the exercise price of such option or warrant.
  • F5 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
  • F7 Under an agreement between the Reporting Person and Venrock Management, LLC (the Management Company), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.
Open filing 0001140361-26-035608 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Shah Nimish P Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (7,657) — exercise price 85
Disposed (D)7,657——0Direct (D) No
F6, F5, F7
  • F6 Each reported option and warrant was disposed of in connection with the Merger in exchange for a cash payment equal to the excess of $135.11 (the per share merger consideration) over the exercise price of such option or warrant.
  • F5 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
  • F7 Under an agreement between the Reporting Person and Venrock Management, LLC (the Management Company), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.
Open filing 0001140361-26-035608 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Shah Nimish P Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Pre-Funded Warrants (Right to Buy) — underlying Common Stock (365,853)
Disposed (D)365,853——0Indirect (I) See footnoteNo
F8, F6, F9, F10
  • F8 The exercise price of each reported warrant is $0.00001 per share.
  • F6 Each reported option and warrant was disposed of in connection with the Merger in exchange for a cash payment equal to the excess of $135.11 (the per share merger consideration) over the exercise price of such option or warrant.
  • F9 The reported warrants had no expiration date and were exercisable immediately upon grant.
  • F10 The reported warrants are held directly by Venrock Opportunities Fund, L.P. (VOF). Venrock Opportunities Management, LLC (VO Management) is the general partner of VOF. The Reporting Person is a voting member of VO Management and expressly disclaims beneficial ownership over all shares held by VOF except to the extent of his indirect pecuniary interests therein.
Open filing 0001140361-26-035608 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Bollinger Lisa Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (18,550) — exercise price 47.86
Disposed (D)18,550——0Direct (D) No
F2, F1
  • F2 Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option.
  • F1 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035610 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Bollinger Lisa Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (8,112) — exercise price 43.85
Disposed (D)8,112——0Direct (D) No
F2, F1
  • F2 Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option.
  • F1 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035610 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Bollinger Lisa Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (14,461) — exercise price 41.66
Disposed (D)14,461——0Direct (D) No
F2, F1
  • F2 Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option.
  • F1 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035610 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Bollinger Lisa Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (7,657) — exercise price 85
Disposed (D)7,657——0Direct (D) No
F2, F1
  • F2 Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option.
  • F1 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035610 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Fox Jennifer A. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)34,824——0Direct (D) No
F1
  • F1 The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the Merger Agreement), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
Open filing 0001140361-26-035612 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Fox Jennifer A. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,370) — exercise price 43.85
Disposed (D)10,370——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035612 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Fox Jennifer A. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (14,461) — exercise price 41.66
Disposed (D)14,461——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035612 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Fox Jennifer A. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (7,657) — exercise price 85
Disposed (D)7,657——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035612 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03HENDERSON MICHAEL THOMAS Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)920,941——0Direct (D) No
F1
  • F1 The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the Merger Agreement), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
Open filing 0001140361-26-035609 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03HENDERSON MICHAEL THOMAS Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (387,012) — exercise price 22.86
Disposed (D)387,012——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035609 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03HENDERSON MICHAEL THOMAS Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (357,036) — exercise price 49.07
Disposed (D)357,036——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035609 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03HENDERSON MICHAEL THOMAS Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (253,016) — exercise price 75.78
Disposed (D)253,016——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035609 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Dambkowski Carl Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)167,123——0Direct (D) No
F1
  • F1 The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the Merger Agreement), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
Open filing 0001140361-26-035613 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Dambkowski Carl Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (110,665) — exercise price 22.86
Disposed (D)110,665——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035613 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Dambkowski Carl Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (124,962) — exercise price 49.07
Disposed (D)124,962——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035613 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Dambkowski Carl Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (83,690) — exercise price 75.78
Disposed (D)83,690——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035613 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)340,855——0Indirect (I) By Fairmount Healthcare Fund II LPNo
F1, F2
  • F1 Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the Merger Agreement), in exchange for a cash payment equal to $135.11 per Share without interest (the Merger Consideration).
  • F2 Fairmount Funds Management LLC (Fairmount) is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Open filing 0001104659-26-105119 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)51,166——0Indirect (I) By Tomas KiselakNo
F1
  • F1 Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the Merger Agreement), in exchange for a cash payment equal to $135.11 per Share without interest (the Merger Consideration).
Open filing 0001104659-26-105119 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)51,166——0Indirect (I) By Peter HarwinNo
F1
  • F1 Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the Merger Agreement), in exchange for a cash payment equal to $135.11 per Share without interest (the Merger Consideration).
Open filing 0001104659-26-105119 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Non-Voting Common Stock — underlying Common Stock (6,743,321)
Disposed (D)6,743,321——0Indirect (I) By Fairmount Healthcare Fund II LPNo
F3, F1, F2
  • F3 The shares of non-voting common stock had no expiration date and were convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may have been changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not have exceeded 19.99%.
  • F1 Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the Merger Agreement), in exchange for a cash payment equal to $135.11 per Share without interest (the Merger Consideration).
  • F2 Fairmount Funds Management LLC (Fairmount) is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Open filing 0001104659-26-105119 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (47,758) — exercise price 17.00
Disposed (D)47,758——0Indirect (I) By Tomas KiselakNo
F5, F4, F6
  • F5 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option.
  • F4 As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the Merger), or became fully vested in connection with the Merger.
  • F6 Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a Fairmount Fund). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock.
Open filing 0001104659-26-105119 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,370) — exercise price 43.85
Disposed (D)10,370——0Indirect (I) By Tomas KiselakNo
F5, F4, F6
  • F5 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option.
  • F4 As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the Merger), or became fully vested in connection with the Merger.
  • F6 Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a Fairmount Fund). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock.
Open filing 0001104659-26-105119 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (14,461) — exercise price 41.66
Disposed (D)14,461——0Indirect (I) By Tomas KiselakNo
F5, F4, F6
  • F5 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option.
  • F4 As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the Merger), or became fully vested in connection with the Merger.
  • F6 Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a Fairmount Fund). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock.
Open filing 0001104659-26-105119 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (7,657) — exercise price 85.00
Disposed (D)7,657——0Indirect (I) By Tomas KiselakNo
F5, F4, F6
  • F5 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option.
  • F4 As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the Merger), or became fully vested in connection with the Merger.
  • F6 Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a Fairmount Fund). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock.
Open filing 0001104659-26-105119 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03McKenna Mark C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)20,000——0Direct (D) No
F1
  • F1 The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the Merger Agreement), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
Open filing 0001140361-26-035615 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03McKenna Mark C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (150,000) — exercise price 23.6
Disposed (D)150,000——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035615 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03McKenna Mark C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,370) — exercise price 43.85
Disposed (D)10,370——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035615 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03McKenna Mark C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (14,461) — exercise price 41.66
Disposed (D)14,461——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035615 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03McKenna Mark C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (7,657) — exercise price 85
Disposed (D)7,657——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035615 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03JONES WILLIAM A JR Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)34,824——0Direct (D) No
F1
  • F1 The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the Merger Agreement), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
Open filing 0001140361-26-035614 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03JONES WILLIAM A JR Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,370) — exercise price 43.85
Disposed (D)10,370——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035614 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03JONES WILLIAM A JR Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (14,461) — exercise price 41.66
Disposed (D)14,461——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035614 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03JONES WILLIAM A JR Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (7,657) — exercise price 85
Disposed (D)7,657——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035614 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Henderson Jane Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)158,371——0Direct (D) No
F1
  • F1 The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the Merger Agreement), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
Open filing 0001140361-26-035611 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Henderson Jane Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (175,345) — exercise price 22.86
Disposed (D)175,345——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035611 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Henderson Jane Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (124,962) — exercise price 49.07
Disposed (D)124,962——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035611 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-03Henderson Jane Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (83,690) — exercise price 75.78
Disposed (D)83,690——0Direct (D) No
F3, F2
  • F3 Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
  • F2 The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Open filing 0001140361-26-035611 Read from the filing’s XML Dispute this row
2026-09-02 Filed 2026-09-03Dambkowski Carl Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)1,375135.06
185,707.5

Derived: shares × price per share. Exact value 185707.50.

167,123Direct (D) No— Open filing 0001140361-26-035613 Read from the filing’s XML Dispute this row
2026-08-07 Filed 2026-08-11Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)31,83817.00
541,246

Derived: shares × price per share. Exact value 541246.00.

330,485Indirect (I) By Fairmount Healthcare Fund II LPNo
F1
  • F1 Fairmount Funds Management LLC (Fairmount) is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Open filing 0001104659-26-094087 Read from the filing’s XML Dispute this row
2026-08-07 Filed 2026-08-11Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)10,37043.85
454,724.5

Derived: shares × price per share. Exact value 454724.50.

340,855Indirect (I) By Fairmount Healthcare Fund II LPNo
F1
  • F1 Fairmount Funds Management LLC (Fairmount) is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Open filing 0001104659-26-094087 Read from the filing’s XML Dispute this row
2026-08-07 Filed 2026-08-11Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (31,838) — exercise price 17
Disposed (D)31,8380—0Direct (D) No
F2, F3
  • F2 This option represented the vested portion of the total right to purchase 47,758 shares of the Issuer's common stock, which vested in three approximately equal annual installments beginning on the first anniversary of the 7/13/2023 grant date.
  • F3 Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the Adviser), Mr. Harwin held the options reported herein for one or more investment vehicles managed by the Adviser (each, a Fairmount Fund). Mr. Harwin was obligated to turn over to the Adviser any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaimed beneficial ownership of the option and underlying common stock.
Open filing 0001104659-26-094087 Read from the filing’s XML Dispute this row
2026-08-07 Filed 2026-08-11Fairmount Funds Management LLC DirectorFairmount Healthcare Fund II L.P. DirectorKiselak Tomas DirectorHarwin Peter Evan Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,370) — exercise price 43.85
Disposed (D)10,3700—0Direct (D) No
F4, F3
  • F4 This option represented the right to purchase 10,370 shares of the Issuer's common stock, which vested on the one-year anniversary of the 6/5/2024 grant date.
  • F3 Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the Adviser), Mr. Harwin held the options reported herein for one or more investment vehicles managed by the Adviser (each, a Fairmount Fund). Mr. Harwin was obligated to turn over to the Adviser any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaimed beneficial ownership of the option and underlying common stock.
Open filing 0001104659-26-094087 Read from the filing’s XML Dispute this row
2026-08-05 Filed 2026-08-07Dambkowski Carl Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)4,12522.86
94,297.5

Derived: shares × price per share. Exact value 94297.50.

173,998Direct (D) Yes— Open filing 0001104659-26-092838 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–4 of 4

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
GLENMEDE TRUST CO NA 8,127 SH322,885 dollarsHigher by 2,007 Prior quarter: 6,120Open filing 0001398344-26-020129 Filed 2026-11-16 Dispute this row
TEACHER RETIREMENT SYSTEM OF TEXAS 4,423 SH587,065 dollarsUnchanged Prior quarter: 4,423Open filing 0000796848-26-000014 Filed 2026-11-12 Dispute this row
IFP Advisors, Inc Partly reported under another manager79 SH10,671 dollarsHigher by 7 Prior quarter: 72Open filing 0001641866-26-000005 Filed 2026-10-16 Dispute this row
Allworth Financial LP 16 SH2,124 dollarsUnchanged Prior quarter: 16Open filing 0001140361-26-042358 Filed 2026-11-06 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Venrock Adviser, LLC 8,493,321 SH
  • BlackRock, Inc. 5,507,032 SH
  • HBK INVESTMENTS L P 2,850,000 SH
  • VANGUARD CAPITAL MANAGEMENT LLC 2,572,119 SH
  • FMR LLC 2,493,137 SH
  • STATE STREET CORP 2,297,743 SH
  • Driehaus Capital Management LLC 1,740,101 SH
  • GOLDMAN SACHS GROUP INC 1,693,341 SH
  • Balyasny Asset Management L.P. 1,665,102 SH
  • GLAZER CAPITAL, LLC 1,641,042 SH
  • Paradigm Biocapital Advisors LP 1,576,385 SH
  • VANGUARD PORTFOLIO MANAGEMENT LLC 1,528,750 SH
  • MILLENNIUM MANAGEMENT LLC 1,491,404 SH
  • Pentwater Capital Management LP 1,425,000 SH
  • MORGAN STANLEY 1,421,681 SH
  • GEODE CAPITAL MANAGEMENT, LLC 1,314,868 SH
  • PERCEPTIVE ADVISORS LLC 1,308,113 SH
  • Jupiter Topco LLC 1,193,626 SH
  • BANK OF AMERICA CORP /DE/ 1,126,139 SH
  • Affinity Asset Advisors, LLC 987,000 SH
  • MERCER GLOBAL ADVISORS INC /ADV 941,283 SH
  • First Light Asset Management, LLC 930,289 SH
  • O'Connor Alternative Investments, LLC 875,000 SH
  • ALLIANCEBERNSTEIN L.P. 775,058 SH
  • T. Rowe Price Investment Management, Inc. 762,183 SH
  • Kryger Capital LLC 742,555 SH
  • Qube Research Technologies Ltd 659,678 SH
  • First Trust Capital Management L.P. 625,182 SH
  • Remedium Capital Partners, LLC 586,691 SH
  • SOROS FUND MANAGEMENT LLC 564,500 SH
  • WELLINGTON MANAGEMENT GROUP LLP 564,326 SH
  • Balyasny Asset Management L.P. 500,000 SH
  • Woodline Partners LP 464,622 SH
  • WHITEBOX ADVISORS LLC 450,001 SH
  • NORTHERN TRUST CORP 445,154 SH
  • Sixth Street Partners Management Company, L.P. 443,658 SH
  • CHARLES SCHWAB INVESTMENT MANAGEMENT INC 443,658 SH
  • AQR Arbitrage LLC 429,900 SH
  • Magnetar Financial LLC 399,123 SH
  • Man Group plc 397,000 SH
  • VANGUARD FIDUCIARY TRUST CO 393,180 SH
  • Opaleye Management Inc. 390,000 SH
  • TIG Advisors, LLC 364,250 SH
  • FRANKLIN RESOURCES INC 363,379 SH
  • JPMORGAN CHASE CO 359,250 SH
  • Cinctive Capital Management LP 350,165 SH
  • LOOMIS SAYLES CO L P 338,664 SH
  • Polar Asset Management Partners Inc. 322,467 SH
  • FRONTIER CAPITAL MANAGEMENT CO LLC 303,739 SH
  • NEXPOINT ASSET MANAGEMENT, L.P. 299,940 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Venrock Healthcare Capital Partners III, L.P. Common Stock, par value $0.00001 per share0.00.0009/03/2026 Filed 2026-09-08SCHEDULE 13D/AAmendment 1Open filing 0001231919-26-001150 Dispute this row
VHCP Co-Investment Holdings III, LLC Common Stock, par value $0.00001 per share0.00.0009/03/2026 Filed 2026-09-08SCHEDULE 13D/AAmendment 1Open filing 0001231919-26-001150 Dispute this row
Venrock Healthcare Capital Partners EG, L.P. Common Stock, par value $0.00001 per share0.00.0009/03/2026 Filed 2026-09-08SCHEDULE 13D/AAmendment 1Open filing 0001231919-26-001150 Dispute this row
VHCP Management III, LLC Common Stock, par value $0.00001 per share0.00.0009/03/2026 Filed 2026-09-08SCHEDULE 13D/AAmendment 1Open filing 0001231919-26-001150 Dispute this row
VHCP Management EG, LLC Common Stock, par value $0.00001 per share0.00.0009/03/2026 Filed 2026-09-08SCHEDULE 13D/AAmendment 1Open filing 0001231919-26-001150 Dispute this row
Bong Y. Koh Common Stock, par value $0.00001 per share0.00.0009/03/2026 Filed 2026-09-08SCHEDULE 13D/AAmendment 1Open filing 0001231919-26-001150 Dispute this row
Nimish Shah Common Stock, par value $0.00001 per share0.00.0009/03/2026 Filed 2026-09-08SCHEDULE 13D/AAmendment 1Open filing 0001231919-26-001150 Dispute this row
Fairmount Funds Management LLC Common Stock, $0.00001 par value0.00.0009/03/2026 Filed 2026-09-03SCHEDULE 13D/AAmendment 7Open filing 0001104659-26-105122 Dispute this row
Fairmount Healthcare Fund II L.P. Common Stock, $0.00001 par value0.00.0009/03/2026 Filed 2026-09-03SCHEDULE 13D/AAmendment 7Open filing 0001104659-26-105122 Dispute this row
Peter Evan Harwin Common Stock, $0.00001 par value0.00.0009/03/2026 Filed 2026-09-03SCHEDULE 13D/AAmendment 7Open filing 0001104659-26-105122 Dispute this row
Tomas Kiselak Common Stock, $0.00001 par value0.00.0009/03/2026 Filed 2026-09-03SCHEDULE 13D/AAmendment 7Open filing 0001104659-26-105122 Dispute this row
FMR LLC COMMON STOCK4.02,493,136.7306/30/2026 Filed 2026-07-08SCHEDULE 13G/AAmendment 4Open filing 0000315066-26-001471 Dispute this row
Abigail P. Johnson COMMON STOCK4.02,493,136.7306/30/2026 Filed 2026-07-08SCHEDULE 13G/AAmendment 4Open filing 0000315066-26-001471 Dispute this row
T. Rowe Price Investment Management, Inc. COMMON STOCK1.3772,96906/30/2026 Filed 2026-07-08SCHEDULE 13G/AAmendment 2Open filing 0001897612-26-000527 Dispute this row
Wellington Management Group LLP Common Stock0.9564,326.0006/30/2026 Filed 2026-07-08SCHEDULE 13G/AAmendment 5Open filing 0000902219-26-000212 Dispute this row
Wellington Group Holdings LLP Common Stock0.9564,326.0006/30/2026 Filed 2026-07-08SCHEDULE 13G/AAmendment 5Open filing 0000902219-26-000212 Dispute this row
Wellington Investment Advisors Holdings LLP Common Stock0.9564,326.0006/30/2026 Filed 2026-07-08SCHEDULE 13G/AAmendment 5Open filing 0000902219-26-000212 Dispute this row
Fairmount Funds Management LLC Common Stock, $0.00001 par value9.846,713,519.0006/18/2026 Filed 2026-06-23SCHEDULE 13D/AAmendment 6Open filing 0001104659-26-076853 Dispute this row
Fairmount Healthcare Fund II L.P. Common Stock, $0.00001 par value9.846,713,519.0006/18/2026 Filed 2026-06-23SCHEDULE 13D/AAmendment 6Open filing 0001104659-26-076853 Dispute this row
Peter Evan Harwin Common Stock, $0.00001 par value9.996,808,789.0006/18/2026 Filed 2026-06-23SCHEDULE 13D/AAmendment 6Open filing 0001104659-26-076853 Dispute this row
Tomas Kiselak Common Stock, $0.00001 par value9.996,808,789.0006/18/2026 Filed 2026-06-23SCHEDULE 13D/AAmendment 6Open filing 0001104659-26-076853 Dispute this row
T. Rowe Price Investment Management, Inc. COMMON STOCK16.810,291,22003/31/2026 Filed 2026-04-08SCHEDULE 13G/AAmendment 1Open filing 0001897612-26-000344 Dispute this row
Fairmount Funds Management LLC Common Stock, $0.00001 par value9.846,666,332.0003/26/2026 Filed 2026-03-27SCHEDULE 13D/AAmendment 5Open filing 0001104659-26-036265 Dispute this row
Fairmount Healthcare Fund II L.P. Common Stock, $0.00001 par value9.846,666,332.0003/26/2026 Filed 2026-03-27SCHEDULE 13D/AAmendment 5Open filing 0001104659-26-036265 Dispute this row
Peter Evan Harwin Common Stock, $0.00001 par value9.996,764,974.0003/26/2026 Filed 2026-03-27SCHEDULE 13D/AAmendment 5Open filing 0001104659-26-036265 Dispute this row
Tomas Kiselak Common Stock, $0.00001 par value9.996,764,974.0003/26/2026 Filed 2026-03-27SCHEDULE 13D/AAmendment 5Open filing 0001104659-26-036265 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 1Open filing 0000102909-26-000604 Dispute this row
T. Rowe Price Investment Management, Inc. COMMON STOCK11.36,213,82702/28/2026 Filed 2026-03-06SCHEDULE 13GOpen filing 0001897612-26-000311 Dispute this row
Fairmount Funds Management LLC Common Stock, $0.00001 par value9.825,948,385.0001/22/2026 Filed 2026-01-22SCHEDULE 13D/AAmendment 4Open filing 0001104659-26-005916 Dispute this row
Fairmount Healthcare Fund II L.P. Common Stock, $0.00001 par value9.825,948,385.0001/22/2026 Filed 2026-01-22SCHEDULE 13D/AAmendment 4Open filing 0001104659-26-005916 Dispute this row
Peter Evan Harwin Common Stock, $0.00001 par value9.996,047,027.0001/22/2026 Filed 2026-01-22SCHEDULE 13D/AAmendment 4Open filing 0001104659-26-005916 Dispute this row
Tomas Kiselak Common Stock, $0.00001 par value9.996,047,027.0001/22/2026 Filed 2026-01-22SCHEDULE 13D/AAmendment 4Open filing 0001104659-26-005916 Dispute this row
RTW Investments, LP Common Stock, $0.00001 par value4.92,712,097.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001493215-26-000028 Dispute this row
Roderick Wong Common Stock, $0.00001 par value4.92,712,097.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001493215-26-000028 Dispute this row
Wellington Management Group LLP Common Stock8.74,746,585.0012/31/2025 Filed 2026-02-10SCHEDULE 13G/AAmendment 4Open filing 0000902219-26-000095 Dispute this row
Wellington Group Holdings LLP Common Stock8.74,746,585.0012/31/2025 Filed 2026-02-10SCHEDULE 13G/AAmendment 4Open filing 0000902219-26-000095 Dispute this row
Wellington Investment Advisors Holdings LLP Common Stock8.74,746,585.0012/31/2025 Filed 2026-02-10SCHEDULE 13G/AAmendment 4Open filing 0000902219-26-000095 Dispute this row
Wellington Management Company LLP Common Stock8.34,746,585.0012/31/2025 Filed 2026-02-10SCHEDULE 13G/AAmendment 4Open filing 0000902219-26-000095 Dispute this row
The Vanguard Group Common Stock5.212,857,82412/31/2025 Filed 2026-01-30SCHEDULE 13GOpen filing 0000102909-26-000084 Dispute this row
Fairmount Funds Management LLC Common Stock, $0.00001 par value9.815,678,239.0010/10/2025 Filed 2025-10-14SCHEDULE 13D/AAmendment 3Open filing 0001104659-25-099401 Dispute this row
Fairmount Healthcare Fund II L.P. Common Stock, $0.00001 par value9.815,678,239.0010/10/2025 Filed 2025-10-14SCHEDULE 13D/AAmendment 3Open filing 0001104659-25-099401 Dispute this row
Peter Evan Harwin Common Stock, $0.00001 par value9.995,776,881.0010/10/2025 Filed 2025-10-14SCHEDULE 13D/AAmendment 3Open filing 0001104659-25-099401 Dispute this row
Tomas Kiselak Common Stock, $0.00001 par value9.995,776,881.0010/10/2025 Filed 2025-10-14SCHEDULE 13D/AAmendment 3Open filing 0001104659-25-099401 Dispute this row
DRIEHAUS CAPITAL MANAGEMENT LLC Common Stock4.682,158,50209/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0000938206-25-000048 Dispute this row
Wellington Management Group LLP Common Stock10.64,885,146.0007/31/2025 Filed 2025-08-05SCHEDULE 13G/AAmendment 3Open filing 0000902219-25-000264 Dispute this row
Wellington Group Holdings LLP Common Stock10.64,885,146.0007/31/2025 Filed 2025-08-05SCHEDULE 13G/AAmendment 3Open filing 0000902219-25-000264 Dispute this row
Wellington Investment Advisors Holdings LLP Common Stock10.64,885,146.0007/31/2025 Filed 2025-08-05SCHEDULE 13G/AAmendment 3Open filing 0000902219-25-000264 Dispute this row
Wellington Management Company LLP Common Stock10.34,885,146.0007/31/2025 Filed 2025-08-05SCHEDULE 13G/AAmendment 3Open filing 0000902219-25-000264 Dispute this row
FMR LLC COMMON STOCK15.06,907,100.0006/30/2025 Filed 2025-08-06SCHEDULE 13G/AAmendment 3Open filing 0000315066-25-001957 Dispute this row
Abigail P. Johnson COMMON STOCK15.06,907,100.0006/30/2025 Filed 2025-08-06SCHEDULE 13G/AAmendment 3Open filing 0000315066-25-001957 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,748,233 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015164,615
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to Apogee Therapeutics, Inc.